$NTLA
Intellia Therapeutics, Inc.

2018 Q1 Form 10-K Financial Statement

#000156459018005544 Filed on March 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017
Revenue $7.469M $6.668M $26.12M
YoY Change 20.18% 18.44% 58.49%
Cost Of Revenue $0.00
YoY Change
Gross Profit $7.469M
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $7.410M $10.21M $28.03M
YoY Change 29.32% 99.41% 66.85%
% of Gross Profit 99.21%
Research & Development $22.49M $21.17M $67.65M
YoY Change 67.47% 86.83% 112.46%
% of Gross Profit 301.15%
Depreciation & Amortization $1.012M $830.0K $3.000M
YoY Change 53.33% 107.5% 171.74%
% of Gross Profit 13.55%
Operating Expenses $22.49M $21.17M $67.65M
YoY Change 67.47% 86.83% 112.46%
Operating Profit -$22.43M -$24.72M -$69.56M
YoY Change 73.23% 128.38% 116.28%
Interest Expense $1.070M $750.0K $2.010M
YoY Change 234.38% 188.46% 279.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$21.36M -$23.96M -$67.54M
YoY Change 69.12% 126.83% 113.51%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$21.36M -$23.96M -$67.54M
YoY Change 69.08% 126.86% 113.51%
Net Earnings / Revenue -285.93% -359.37% -258.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$508.1K -$611.4K -$1.876M
COMMON SHARES
Basic Shares Outstanding 42.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $327.8M $340.7M $340.7M
YoY Change 27.25% 24.74% 24.75%
Cash & Equivalents $327.8M $340.7M $340.7M
Short-Term Investments $0.00
Other Short-Term Assets $2.500M $3.700M $3.700M
YoY Change 127.27% 105.56% 105.56%
Inventory
Prepaid Expenses
Receivables $7.466M $10.47M $10.50M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $337.7M $354.8M $354.8M
YoY Change 29.36% 26.14% 26.13%
LONG-TERM ASSETS
Property, Plant & Equipment $16.01M $15.27M $15.30M
YoY Change 40.22% 43.7% 44.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.815M $6.133M $6.100M
YoY Change -14.07% -12.82% -12.86%
Total Long-Term Assets $21.83M $21.41M $21.40M
YoY Change 20.02% 21.19% 20.9%
TOTAL ASSETS
Total Short-Term Assets $337.7M $354.8M $354.8M
Total Long-Term Assets $21.83M $21.41M $21.40M
Total Assets $359.5M $376.2M $376.2M
YoY Change 28.75% 25.84% 25.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.916M $2.172M $2.200M
YoY Change 33.61% -53.31% -53.19%
Accrued Expenses $6.605M $7.999M $8.000M
YoY Change 85.59% 35.58% 35.59%
Deferred Revenue $21.19M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.58M $31.36M $31.40M
YoY Change 2.7% 2.05% 2.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $131.0K $168.0K $44.30M
YoY Change -65.34% -42.66% -24.14%
Total Long-Term Liabilities $131.0K $168.0K $44.30M
YoY Change -65.34% -42.66% -24.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.58M $31.36M $31.40M
Total Long-Term Liabilities $131.0K $168.0K $44.30M
Total Liabilities $25.71M $31.53M $75.60M
YoY Change 1.68% 1.62% -15.15%
SHAREHOLDERS EQUITY
Retained Earnings -$121.1M
YoY Change 126.08%
Common Stock $421.7M
YoY Change 60.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $295.5M $300.6M $300.6M
YoY Change
Total Liabilities & Shareholders Equity $359.5M $376.2M $376.2M
YoY Change 28.73% 25.84% 25.82%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$21.36M -$23.96M -$67.54M
YoY Change 69.08% 126.86% 113.51%
Depreciation, Depletion And Amortization $1.012M $830.0K $3.000M
YoY Change 53.33% 107.5% 171.74%
Cash From Operating Activities -$17.77M -$21.31M -$65.28M
YoY Change 55.88% 47.88% -280.77%
INVESTING ACTIVITIES
Capital Expenditures $1.850M -$2.400M $10.09M
YoY Change -55.55% -29.62% 63.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.850M -$2.400M -$10.09M
YoY Change -55.53% -29.62% 63.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $141.0M
YoY Change -17.31%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.720M 142.1M 143.0M
YoY Change 13340.0% 54561.54% -14.54%
NET CHANGE
Cash From Operating Activities -17.77M -21.31M -65.28M
Cash From Investing Activities -1.850M -2.400M -10.09M
Cash From Financing Activities 6.720M 142.1M 143.0M
Net Change In Cash -12.90M 118.4M 67.61M
YoY Change -16.83% -774.32% -65.72%
FREE CASH FLOW
Cash From Operating Activities -$17.77M -$21.31M -$65.28M
Capital Expenditures $1.850M -$2.400M $10.09M
Free Cash Flow -$19.62M -$18.91M -$75.37M
YoY Change 26.08% 71.91% -351.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
340678000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6133000
CY2017Q4 us-gaap Assets
Assets
376235000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2172000
CY2017 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42387435
CY2017Q2 dei Entity Public Float
EntityPublicFloat
235300000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
273064000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7999000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-69555000
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31840000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11170000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8283000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67647000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28025000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16798000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
95672000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
48638000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
19453000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-67543000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-31634000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-12397000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.42
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-51.02
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22222000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
243000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31359000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2994000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-166000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
15322000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4017000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5454000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1893000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
979000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-488000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1784000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2394000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3050000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121113000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
300597000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
376235000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42384623
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42384623
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
21188000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20178000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30730000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
44111000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
58109000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
168000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
293000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2017 us-gaap License And Services Revenue
LicenseAndServicesRevenue
26117000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
16479000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6044000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
421706000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263403000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53570000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
209837000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
298969000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36018540
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36018540
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-32159000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
2012000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
74661000
CY2015 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
1100000
CY2016 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
CY2015 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
2671000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
170507000
CY2016 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
259000
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2764000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
142981000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
167304000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
70288000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67543000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31634000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13409000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1012000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36006000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
7566000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1984000
CY2015 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-1012000
CY2015 ntla Effect Of Reorganization
EffectOfReorganization
-20671000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
685000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-21201000
CY2016 ntla Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
88557000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
167139000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
259000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6715000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
141000000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1156000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
825000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15322000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1104000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
328000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-13000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
6715000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1308000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1012000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
525000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
335000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
805000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12988000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
67975000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9312000
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
76000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
150000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-65276000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
36109000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1763000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2554000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10091000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6165000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2554000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
67614000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
805000
CY2015 ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
600000
CY2016 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
600000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
141000000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1156000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2017 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
825000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
602000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
197248000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-902000
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6435000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-125000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-30000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10091000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6165000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
65971000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9845000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3090000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
219000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-23963000
CY2015 ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
970000
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
88557000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.&#8221;) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the valuation of common and incentive units for the periods prior to the Company&#8217;s stock becoming publicly traded. Estimates are periodically reviewed in light of changes in circumstances, facts and experiences. Actual results may differ materially from management&#8217;s estimates, judgments and assumptions. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash and cash equivalents may potentially be subject to concentrations of credit risk. The Company generally maintains balances in various accounts in excess of federally insured limits with financial institutions that management believes to be of high credit quality. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable represent amounts due from collaboration partners. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. As of December&#160;31, 2017 and 2016, the Company&#8217;s two collaboration partners, Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;) and Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;), accounted for all of the Company&#8217;s accounts receivable. </p></div>
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
330896000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
330896000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
270448000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270448000
CY2017 ntla Percentage Likelihood Of Realization Required To Record Tax Benefit
PercentageLikelihoodOfRealizationRequiredToRecordTaxBenefit
0.500
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
0
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19601000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12058000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4329000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1430000
CY2017 us-gaap Depreciation
Depreciation
3000000
CY2016 us-gaap Depreciation
Depreciation
1100000
CY2015 us-gaap Depreciation
Depreciation
300000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4773000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2703000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3226000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3197000
CY2015 ntla Collaboration Consideration Allocated To Equity
CollaborationConsiderationAllocatedToEquity
2600000
CY2015 us-gaap Income Tax Effects Allocated Directly To Equity
IncomeTaxEffectsAllocatedDirectlyToEquity
1000000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.069
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2015 ntla Effective Income Tax Rate Reconciliation Intraperiod Tax Allocation
EffectiveIncomeTaxRateReconciliationIntraperiodTaxAllocation
0.067
CY2015 ntla Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.022
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.034
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.028
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.018
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.036
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.019
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.011
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.187
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.220
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.416
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.360
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.076
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1303000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2035000
CY2017Q4 ntla Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
502000
CY2016Q4 ntla Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
785000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9406000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13751000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5817000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1873000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
15913000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1193000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3248000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1940000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1112000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
1139000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37301000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22716000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35372000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20549000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1929000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2167000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1929000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2167000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1929000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2167000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
36700000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
27800000
CY2017 ntla Deferred Tax Assets Operating Loss Carryforwards Expiration Year
DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear
2034
CY2017 ntla Deferred Tax Assets Operating Loss Carryforwards Expiration Description
DeferredTaxAssetsOperatingLossCarryforwardsExpirationDescription
Begin to expire in 2034
CY2017 ntla Deferred Tax Assets Tax Credit Carryforwards Research Expiration Description
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationDescription
Begin to expire in 2034 and 2029
CY2017 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
14800000
CY2016 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
13100000
CY2015 ntla Increase In Deferred Tax Assets Valuation Allowance
IncreaseInDeferredTaxAssetsValuationAllowance
3800000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017 ntla Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Asset Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxBenefit
12600000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
90462
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
479822
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.69
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.34
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.90
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2500000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.24
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.880
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.826
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3040214
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2691157
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
141759
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
884164
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4705448
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1685074
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.35
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.26
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.16
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.55
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.09
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.06
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M17D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M3D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35087000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
17172000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
27200000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5185000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4402000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23764000
CY2017 ntla Accretion Of Redeemable Preferred Stock
AccretionOfRedeemablePreferredStock
0
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6215000
CY2017Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5917000
CY2017Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7317000
CY2017Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6668000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13431000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15565000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17481000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21170000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5732000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6369000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5711000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10213000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
19163000
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
21934000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
23192000
CY2017Q4 us-gaap Costs And Expenses
CostsAndExpenses
31383000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12948000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16017000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15875000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-24715000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
317000
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
424000
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
519000
CY2017Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
752000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12631000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-15593000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-15356000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34723000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34916000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35189000
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39155000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1777000
CY2016Q2 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4206000
CY2016Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
4869000
CY2016Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
5627000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5225000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7423000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7861000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11331000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3246000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3729000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4705000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5118000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
8471000
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
11152000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
12566000
CY2016Q4 us-gaap Costs And Expenses
CostsAndExpenses
16449000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6694000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6946000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7697000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10822000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
46000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
215000
CY2016Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
259000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6689000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7482000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-10563000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.89
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
676000
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19121000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34316000
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34507000

Files In Submission

Name View Source Status
0001564590-18-005544-index-headers.html Edgar Link pending
0001564590-18-005544-index.html Edgar Link pending
0001564590-18-005544.txt Edgar Link pending
0001564590-18-005544-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201803132345292496403.jpg Edgar Link pending
g201803132345449456404.jpg Edgar Link pending
g201803132345453476405.jpg Edgar Link pending
ntla-10k_20171231.htm Edgar Link pending
ntla-20171231.xml Edgar Link completed
ntla-20171231.xsd Edgar Link pending
ntla-20171231_cal.xml Edgar Link unprocessable
ntla-20171231_def.xml Edgar Link unprocessable
ntla-20171231_lab.xml Edgar Link unprocessable
ntla-20171231_pre.xml Edgar Link unprocessable
ntla-ex211_373.htm Edgar Link pending
ntla-ex231_9.htm Edgar Link pending
ntla-ex311_8.htm Edgar Link pending
ntla-ex312_7.htm Edgar Link pending
ntla-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending